Carcinogenesis, Vol. 22, No. 12, 1939-1946,
December 2001
© 2001 Oxford University Press
CANCER BIOLOGY |
The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange
1 Mammalian DNA Repair Laboratory, School of Biological Sciences, Donnan Laboratories, University of Liverpool, Liverpool, L69 7ZD, UK,
2 Department of Pediatric Oncology, Dana-Farber Cancer Institute and Department of Pediatrics, Children's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA,
3 School of Biomedical Sciences, University of St. Andrews, St Andrews, KY16 9TS, UK
4 Department Experimental Radiation Oncology, MD Anderson Cancer Centre, 1515 Holcombe Boulevard, Box 066, Houston, Texas 77030, USA
Fanconi anemia (FA) is a human autosomal disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinking agents such as mitomycin C and diepoxybutane. Six FA genes have been cloned including a gene designated XRCC9 (for X-ray Repair Cross Complementing), isolated using a mitomycin C-hypersensitive Chinese hamster cell mutant termed UV40, and subsequently found to be identical to FANCG. A nuclear complex containing the FANCA, FANCC, FANCE, FANCF and FANCG proteins is needed for the activation of a sixth FA protein FANCD2. When monoubiquitinated, the FANCD2 protein co-localizes with the breast cancer susceptibility protein BRCA1 in DNA damage induced foci. In this study, we have assigned NM3, a nitrogen mustard-hypersensitive Chinese hamster mutant to the same genetic complementation group as UV40. NM3, like human FA cell lines (but unlike UV40) exhibits a normal spontaneous level of sister chromatid exchange. We show that both NM3 and UV40 are also hypersensitive to other DNA crosslinking agents (including diepoxybutane and chlorambucil) and to non-crosslinking DNA damaging agents (including bleomycin, streptonigrin and EMS), and that all these sensitivities are all corrected upon transfection of the human FANCG/XRCC9 cDNA. Using immunoblotting, NM3 and UV40 were found not to express the active monoubiquitinated isoform of the FANCD2 protein, although expression of the FANCD-L isoform was restored in the FANCG cDNA transformants, correlating with the correction of mutagen-sensitivity. These data indicate that cellular resistance to these DNA damaging agents requires FANCG and that the FA gene pathway, via its activation of FANCD2 and that protein's subsequent interaction with BRCA1, is involved in maintaining genomic stability in response not only to DNA interstrand crosslinks but also a range of other DNA damages including DNA strand breaks. NM3 and other `FA-like' Chinese hamster mutants should provide an important resource for the study of these processes in mammalian cells.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. H. Wu, J. B. Wilson, A. M. Wolfreys, A. Scott, and N. J. Jones Optimization of the comet assay for the sensitive detection of PUVA-induced DNA interstrand cross-links Mutagenesis, March 1, 2009; 24(2): 173 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gallmeier and S. E. Kern Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models Clin. Cancer Res., January 1, 2007; 13(1): 4 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zienolddiny, D. Campa, H. Lind, D. Ryberg, V. Skaug, L. Stangeland, D. H. Phillips, F. Canzian, and A. Haugen Polymorphisms of DNA repair genes and risk of non-small cell lung cancer Carcinogenesis, March 1, 2006; 27(3): 560 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. van der Heijden, J. R. Brody, D. A. Dezentje, E. Gallmeier, S. C. Cunningham, M. J. Swartz, A. M. DeMarzo, G. J. A. Offerhaus, W. H. Isacoff, R. H. Hruban, et al. In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor Clin. Cancer Res., October 15, 2005; 11(20): 7508 - 7515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Qiao, J. Mi, J. B. Wilson, G. Zhi, N. R. Bucheimer, N. J. Jones, and G. M. Kupfer Phosphorylation of Fanconi Anemia (FA) Complementation Group G Protein, FANCG, at Serine 7 Is Important for Function of the FA Pathway J. Biol. Chem., October 29, 2004; 279(44): 46035 - 46045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mi, F. Qiao, J. B. Wilson, A. A. High, M. J. Schroeder, P. T. Stukenberg, A. Moss, J. Shabanowitz, D. F. Hunt, N. J. Jones, et al. FANCG Is Phosphorylated at Serines 383 and 387 during Mitosis Mol. Cell. Biol., October 1, 2004; 24(19): 8576 - 8585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hussain, J. B. Wilson, A. L. Medhurst, J. Hejna, E. Witt, S. Ananth, A. Davies, J.-Y. Masson, R. Moses, S. C. West, et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways Hum. Mol. Genet., June 15, 2004; 13(12): 1241 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Lamerdin, N. A. Yamada, J. W. George, B. Souza, A. T. Christian, N. J. Jones, and L. H. Thompson Characterization of the hamster FancG/Xrcc9 gene and mutations in CHO UV40 and NM3 Mutagenesis, May 1, 2004; 19(3): 237 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamamoto, M. Ishiai, N. Matsushita, H. Arakawa, J. E. Lamerdin, J.-M. Buerstedde, M. Tanimoto, M. Harada, L. H. Thompson, and M. Takata Fanconi Anemia FANCG Protein in Mitigating Radiation- and Enzyme-Induced DNA Double-Strand Breaks by Homologous Recombination in Vertebrate Cells Mol. Cell. Biol., August 1, 2003; 23(15): 5421 - 5430. [Abstract] [Full Text] [PDF]
|
|